Volume 26, Issue 118 (September & October 2018)                   J Adv Med Biomed Res 2018, 26(118): 28-33 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Torabi M, Samareh Fekri M, Azizi Shoul S, Naghibzadeh Thahami A, Moeinaddini S. Evaluation of Prognostic Factors of Mortality in Patients with Chronic Obstructive Pulmonary Disease. J Adv Med Biomed Res 2018; 26 (118) :28-33
URL: http://journal.zums.ac.ir/article-1-4940-en.html
Evaluation of Prognostic Factors of Mortality in Patients with Chronic Obstructive Pulmonary Disease
Mehdi Torabi * 1, Mitra Samareh Fekri2 , Sara Azizi Shoul3 , Ahmad Naghibzadeh Thahami4 , Shiva Moeinaddini5
1- Dept. of Emergency Medicine, Faculty of Medicine, Kerman University of Medical Sciences, Kerman, Iran , mtorabi1390@yahoo.com
2- Pulmonology Cardiovascular Research Center, Institute of Basic and clinical physiology sciences, Kerman University of Medical Sciences, Kerman, Iran
3- Dept. of Emergency Medicine, Faculty of Medicine, Kerman University of Medical Sciences, Kerman, Iran
4- Dept. Epidemiology, Research Center for Modeling in Health, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran
5- Dept. of Emergency Medicine, Faculty of Medicine, Rafsanjan University of Medical Sciences, Kerman, Iran
Abstract:   (149156 Views)

Background and Objective: Chronic Obstructive Pulmonary Disease (COPD) is a chronic obstructive and irreversible disease which has a high mortality and morbidity rate. Systemic inflammation and the thrombotic process can influence the prognosis of these patients. The objectives of this study were to evaluate prognostic effects of CBC indices (WBC, PMN, MPV, RDW), forced expiratory volume-one second (FEV1) and mean Pulmonary Artery Pressure (mPAP) in the prognosis of COPD patients with acute exacerbation of the disease.
Material and Methods: This cross-sectional study was performed on exacerbated COPD patients who were admitted to the emergency department, Afzalipour Hospital, Kerman, Iran during 2016-2017. For all the patients, CBC was assessed as they arrived then Pulmonary Function Test and echocardiography were conducted.  In order to create the final model, we employed multivariate regression analysis.
Results: A total of 1078 patients were enrolled during one year, of which 58.3% were male. In multivariate analysis, White blood cells (WBC), Polymorphonuclear leukocytes (PMN), Mean platelet volume (MPV), Red Cell Distribution Width (RDW), FEV1 and mPAP were the six variables which are independently associated with hospital mortality and ICU admission. Sensitivity, specificity and area under the curve for these six variables model were 78.5, 92 and 86% respectively.
Conclusion: Since the inflammatory and thrombotic events are influential in the prognosis of COPD patients, it may be possible to predict patients outcome with CBC related indices (WBC, PMN, MPV and RDW), although other important risk factors such as pulmonary hypertension and FEV1 decrease should be considered as well.

Keywords: COPD, Mean platelet volume, Red Cell Distribution Width, Hospital mortality
Full-Text [PDF 347 kb]   (156493 Downloads) |   |   Full-Text (HTML)  (3060 Views)  
✅ Since the inflammatory and thrombotic events are influential in the prognosis of COPD patients, it may be possible to predict patients outcome with CBC related indices (WBC, PMN, MPV and RDW), although other important risk factors such as pulmonary hypertension and FEV1 decrease should be considered as well.

Type of Study: Original Article | Subject: Clinical medicine
Received: 2017/10/30 | Accepted: 2018/07/17 | Published: 2018/08/1
References
1. Agudelo Higuita NI, Brunetti E, McCloskey C. Cystic echinococcosis. J Clin Microbiol. 2016; 54(3): 518-23. [DOI:10.1128/JCM.02420-15] [PMID] [PMCID]
2. World Health Organisation. Echinococcosis. World Health Organisation, Geneva, Switzerland. http://www.who.int/mediacentre/factsheets/fs377/en. Accessed on 12 Feb 2018.
3. Brunetti E, Kern P, Vuitton DA, Writing Panel for the WHO-IWGE. Expert consensus for the diagnosis and treatment of cystic and alveolar echinococcosis in humans. Acta trop. 2010; 114(1): 1-16. [DOI:10.1016/j.actatropica.2009.11.001] [PMID]
4. McManus DP, Gray DJ, Zhang W, Yang Y. Diagnosis, treatment, and management of echinococcosis. BMJ. 2012; 344: e3866. [DOI:10.1136/bmj.e3866] [PMID]
5. Teggi A, Lastilla MG, De Rosa F. Therapy of Human Hydatid-Disease with Mebendazole and Albendazole. Antimicrob Agents Chemother. 1993; 37(8): 1679-84. doi:10.1128/aac.37.8.1679 [DOI:10.1128/AAC.37.8.1679] [PMID] [PMCID]
6. Moro P, Schantz PM. Echinococcosis: a review. Int J Infect Dis. 2009; 13(2): 125-33. [DOI:10.1016/j.ijid.2008.03.037] [PMID]
7. Chai JY. Praziquantel treatment in trematode and cestode infections: an update. Infect Chemother. 2013; 45(1): 32-43 [DOI:10.3947/ic.2013.45.1.32] [PMID] [PMCID]
8. Bygott JM, Chiodini PL. Praziquantel: neglected drug? Ineffective treatment? Or therapeutic choice in cystic hydatid disease? Acta Trop. 2009; 111(2): 95-101. [DOI:10.1016/j.actatropica.2009.04.006] [PMID]
9. Casado N, Urrea-Paris MA, Moreno MJ, Rodriguez-Caabeiro F. Combined praziquantel and albendazole chemoprophylaxis in experimental hydatidosis. Parasitol Res. 2001; 87(9): 787-9. [DOI:10.1007/s004360100443] [PMID]
10. Mohamed AE, Yasawy MI, Al Karawi MA. Combined albendazole and praziquantel versus albendazole alone in the treatment of hydatid disease. Hepato-Gastroenterol. 1998; 45(23): 1690-4.
11. Nazligul Y, Kucukazman M, Akbulut S. Role of chemotherapeutic agents in the management of cystic echinococcosis. Int Surg. 2015; 100(1): 112-4. [DOI:10.9738/INTSURG-D-14-00068.1] [PMID] [PMCID]
12. Urrea-Paris MA, Casado N, Moreno MJ, Rodriguez-Caabeiro F. Chemoprophylactic praziquantel treatment in experimental hydatidosis. Parasitol Res. 2001; 87(6): 510-2. [DOI:10.1007/s004360100390]
13. Elissondo M, Dopchiz M, Ceballos L, et al. In vitro effects of flubendazole on Echinococcus granulosus protoscoleces. Parasitol Res. 2006; 98(4): 317-23. [DOI:10.1007/s00436-005-0026-6] [PMID]
14. Elissondo M, Ceballos L, Dopchiz M, et al. In vitro and in vivo effects of flubendazole on Echinococcus granulosus metacestodes. Parasitol Res. 2007; 100(5): 1003-9. [DOI:10.1007/s00436-006-0381-y] [PMID]
15. Elissondo MC, Ceballos L, Alvarez L, Bruni SS, Lanusse C, Denegri G. Flubendazole and ivermectin in vitro combination therapy produces a marked effect on Echinococcus granulosus protoscoleces and metacestodes. Parasitol Res. 2009; 105(3): 835-42. [DOI:10.1007/s00436-009-1469-y] [PMID]
16. Ceballos L, Elissondo C, Bruni SS, Denegri G, Lanusse C, Alvarez L. Comparative performances of flubendazole and albendazole in cystic echinococcosis: ex vivo activity, plasma/cyst disposition, and efficacy in infected mice. Antimicrob agents chemother. 2011; 55(12): 5861-7. doi:10.1128/AAC.05105-11 [DOI:10.1128/AAC.05105-11] [PMID] [PMCID]
17. Ceballos L, Virkel G, Elissondo C, et al. A pharmacology-based comparison of the activity of albendazole and flubendazole against Echinococcus granulosus metacestode in sheep. Acta trop. 2013; 127(3): 216-25. [DOI:10.1016/j.actatropica.2013.05.004] [PMID]
18. Haniloo A, Ghasemi F, Shikhi Ak, Ghavami MB. Immunoregulatory cytokine (TGF-ß And IL-10) responses in mice inoculated with protoscoleces and major hydatid fluidantigens of cystic echinococcosis. Iranian J Parasitol. 2008; 3(3): 18-23.
19. Haniloo A, Najafi F, Fazaeli A, Nourian A. Comparison and evaluation of Echinococcus granulosus protoscoleces excretory/secretory proteins in PBS complemented with glucose, DMEM and RPMI culture media. J Zanjan Univ Med Sci. 2011; 19 (74): 44-53.
20. Liu CS, Zhang HB, Yin JH, Jiang B, Han XM. Echinococcus granulosus: Suitable in vitro protoscolices culture density. Biomed Environ Sci. 2013; 26(11): 912-5
21. Walker M, Rossignol JF, Torgerson P, Hemphill A. In vitro effects of nitazoxanide on Echinococcus granulosus protoscoleces and metacestodes. J Antimicrob Chemother. 2004; 54(3): 609-16. [DOI:10.1093/jac/dkh386] [PMID]
22. Naguleswaran A, Spicher M, Vonlaufen N, et al. In vitro metacestodicidal activities of genistein and other isoflavones against Echinococcus multilocularis and Echinococcus granulosus. Antimicrob Agents Chemother. 2006; 50(11): 3770-8. [DOI:10.1128/AAC.00578-06] [PMID] [PMCID]
23. Casado N, Perez-Serrano J, Denegri G, Rodriguez-Caabeiro F. Development of a chemotherapeutic model for the in vitro screening of drugs against Echinococcus granulosus cysts: The effects of an albendazole albendazole sulphoxide combination. Int J Parasitol. 1996; 26(1): 59-65. [DOI:10.1016/0020-7519(95)00095-X]
24. Perez-Serrano J, Casado N, Denegri G, Rodriguez-Caabeiro F. The effects of albendazole and albendazole sulfoxide combination-therapy on Echinococcus granulosus in vitro. Int J Parasitol. 1994; 24(2): 219-24. [DOI:10.1016/0020-7519(94)90029-9]
25. Thompson RC, Reynoldson JA, Riddler CR. Praziquantel adversely affects protoscoleces of Echinococcus granulosus in vitro. J Helminthol. 1986; 60(4): 279-86. [DOI:10.1017/S0022149X00008488]
26. Zheng XS, Duan CZ, Xiao ZD, Yao BA. Transdermal delivery of praziquantel: effects of solvents on permeation across rabbit skin. Biol Pharm Bull. 2008; 31(5): 1045-8. [DOI:10.1248/bpb.31.1045] [PMID]
27. Urrea-Paris MA, Moreno MJ, Casado N, Rodriguez-Caabeiro F. In vitro effect of praziquantel and albendazole combination therapy on the larval stage of Echinococcus granulosus. Parasitol Res. 2000; 86(12): 957-64. [DOI:10.1007/PL00008526]
28. Perez-Serrano J, Denegri G, Casado N, Rodriguez-Caabeiro F. In vivo effect of oral albendazole and albendazole sulphoxide on development of secondary echinococcosis in mice. Int J Parasitol. 1997; 27(11): 1341-5. [DOI:10.1016/S0020-7519(97)00105-7]
29. Lacey E. The role of the cytoskeletal protein, tubulin, in the mode of action and mechanism of drug resistance to benzimidazoles. Int J Parasitol. 1988; 18(7): 885-936. [DOI:10.1016/0020-7519(88)90175-0]
Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2025 CC BY-NC 4.0 | Journal of Advances in Medical and Biomedical Research

Designed & Developed by : Yektaweb